Centene Corporation (CNC)
NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
$67.06+1.42%
Close 2026-07-08 · 1-day change
Reading CNC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CNC free→NYSEHealth CareHealthcare PlansSnapshot 2026-07-08
Reading CNC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CNC free→QuarterlyIQ Insights · CNC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Director — Lauren Tyler: The Board of Directors increased its size and elected Lauren Tyler as a new director.
The company has made internal promotions and redefined the list of executive officers.
shall be deemed to be furnished and not filed: 99.1 Press release of Centene Corporation issued April 28, 2026, as to financial results for the first quarter ended March 31, 2026. EXHIBIT INDEX Exhibit Number Description 99.1* Press release of Centene Corporation issued April 28, 2026 as to financial results for the first quarter ended March 31, 2026 104 Cover page information from Centene Corporation’s Current Report on Form 8-K filed on April 28, 2026 formatted in Inline Extensible Business…
Corporate Controller and Chief Accounting Officer — Theodore Pienkos: Theodore Pienkos was promoted to Corporate Controller and Chief Accounting Officer.
OTHER EVENTS On March 10, 2026, the Company delivered a notice of partial redemption to redeem on March 25, 2026 (the redemption date) $1,000,000,000 aggregate principal amount of its outstanding 4.25% Notes due December 15, 2027 (the 2027 Notes) in accordance with the terms of the 2027 Notes and the Indenture dated as of December 6, 2019 between the Company and The Bank of New York Mellon Trust Company, N.A. as trustee. Following the redemption, approximately $1,186,664,000 of the 2027 Notes…
REGULATION FD DISCLOSURE Centene Corporation (the Company) will be presenting at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, at 8:30 a.m. EDT. A simultaneous live audio webcast of the presentation on March 10 will be available at https://event.webcasts.com/starthere.jsp?ei=1753406&tp_key=d357b0a0a7&tp_special=8. A webcast replay will be available following the presentation via the Company's website at www.centene.com, under the Investors section. During t…
REGULATION FD DISCLOSURE Members of Centene Corporation's (the Company's) senior management team will meet with investors the week of February 23, 2026. Consistent with the Company's guidance previously provided on February 6, 2026, the senior management team plans to reaffirm the Company's 2026 full year GAAP diluted earnings per share (EPS) guidance of greater than $1.98 and its full year adjusted diluted EPS guidance of greater than $3.00. Non-GAAP Financial Presentation The Company is pro…
shall be deemed to be furnished and not filed: 99.1 Press release of Centene Corporation issued February 6, 2026, as to financial results for the fourth quarter and year ended December 31, 2025 99.2 Centene Corporation 2026 Guidance Presentation EXHIBIT INDEX Exhibit Number Description 99.1* Press release of Centene Corporation issued February 6, 2026 as to financial results for the fourth quarter and year ended December 31, 2025 99.2* Centene Corporation 2026 Guidance Presentation 104 Cover…
REGULATION FD DISCLOSURE Centene Corporation (the Company) will appear at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at 10:15 a.m. EST. At the conference, and in subsequent discussions with investors, members of management will discuss the Company's financial outlook, which is consistent with its previously-issued full year 2025 GAAP forecast of a diluted loss per share not to exceed $(12.85) and full year 2025 adjusted diluted earnings per share (EPS) forecast o…
shall be deemed to be furnished and not filed: 99.1 Press release of Centene Corporation issued October 29, 2025, as to financial results for the third quarter ended September 30, 2025. EXHIBIT INDEX Exhibit Number Description 99.1* Press release of Centene Corporation issued October 29, 2025 as to financial results for the third quarter ended September 30, 2025. 104 Cover page information from Centene Corporation’s Current Report on Form 8-K filed on October 29, 2025 formatted in Inline Exte…
REGULATION FD DISCLOSURE Centene Corporation (the Company) will be participating at the Deutsche Bank 2025 Healthcare Summit on Thursday, September 11, 2025, at 8:00 a.m. EDT. Members of management will discuss the Company’s business and financial results through August, which are consistent with its previously-issued full year 2025 forecast of approximately $1.75 adjusted diluted earnings per share (EPS). A simultaneous live audio webcast of Centene's participation in the summit on September…
Director — Thomas R. Greco: Mr. Greco resigned due to increased professional responsibilities at another company.
Director — Wayne S. DeVeydt: Mr. DeVeydt resigned from his position as Director, and the Board reduced its size.
shall be deemed to be furnished and not filed: 99.1 Press release of Centene Corporation issued July 25, 2025, as to financial results for the second quarter ended June 30, 2025. EXHIBIT INDEX Exhibit Number Description 99.1* Press release of Centene Corporation issued July 25, 2025 as to financial results for the second quarter ended June 30, 2025. 104 Cover page information from Centene Corporation’s Current Report on Form 8-K filed on July 25, 2025 formatted in Inline Extensible Business R…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION (a) On July 1, 2025, Centene Corporation issued a press release withdrawing the previously-issued 2025 GAAP and adjusted diluted earnings per share guidance, including the underlying guidance elements. The full text of the press release is included as Exhibit 99.1 to this report and incorporated by reference. The information contained in the website cited in the press release is not a part of this report. The information contained in this Form 8-K…
REGULATION FD DISCLOSURE On May 6, 2025, members of Centene Corporation's (the Company's) senior management team will meet with investors. Consistent with the Company's guidance previously provided on April 25, 2025, the senior management team plans to reaffirm the Company's 2025 full year GAAP diluted earnings per share (EPS) guidance floor of greater than $6.19 and its full year adjusted diluted EPS guidance floor of greater than $7.25. Non-GAAP Financial Presentation The Company is providi…
shall be deemed to be furnished and not filed: 99.1 Press release of Centene Corporation issued April 25, 2025, as to financial results for the first quarter ended March 31, 2025. EXHIBIT INDEX Exhibit Number Description 99.1* Press release of Centene Corporation issued April 25, 2025 as to financial results for the first quarter ended March 31, 2025. 104 Cover page information from Centene Corporation’s Current Report on Form 8-K filed on April 25, 2025 formatted in Inline Extensible Busines…
REGULATION FD DISCLOSURE Centene Corporation will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 2:30 p.m. EDT. A simultaneous live audio webcast of the presentation on March 12 will be available at https://event.webcasts.com/starthere.jsp?ei=1711439&tp_key=abafa719df&tp_special=8. A webcast replay will be available following the presentation via the Company's website at www.centene.com, under the Investors section. During the presentat…
TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT. Please see
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. On March 5, 2025 (the Effective Date), Centene Corporation, a Delaware corporation (Centene), entered into a new Credit Agreement (the New Credit Agreement) by and among Centene, the lenders from time to time party thereto and Wells Fargo Bank, National Association (Wells Fargo), as the administrative agent for the lenders, and, substantially contemporaneously therewith, Centene terminated all outstanding commitments and repaid all outstanding oblig…
CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT. Please see
REGULATION FD DISCLOSURE On March 4, 2025, members of Centene Corporation's (the Company) senior management team will meet with investors. Consistent with the Company's guidance previously provided on February 4, 2025, the senior management team plans to reaffirm the Company's 2025 full year adjusted diluted earnings per share (EPS) guidance floor of greater than $7.25. Non-GAAP Financial Presentation The Company is providing certain non-GAAP financial measures in this Form 8-K as the Company…
Director — Kenneth Tanji: The Board of Directors elected Kenneth Tanji as a new director.
shall be deemed to be furnished and not filed: 99.1 Press release of Centene Corporation issued February 4, 2025, as to financial results for the fourth quarter and year ended December 31, 2024. EXHIBIT INDEX Exhibit Number Description 99.1* Press release of Centene Corporation issued February 4, 2025 as to financial results for the fourth quarter and year ended December 31, 2024. 104 Cover page information from Centene Corporation’s Current Report on Form 8-K filed on February 4, 2025 format…
REGULATION FD DISCLOSURE On November 13, 2024, members of Centene Corporation's (the "Company") senior management team will meet with investors. Consistent with the Company's guidance previously provided on October 25, 2024, the senior management team plans to reaffirm the Company’s 2024 full year adjusted diluted earnings per share (EPS) guidance of greater than $6.80. The senior management team also plans to reiterate that the Company expects to grow adjusted diluted EPS in 2025 and beyond.…
Importance-ranked changes since the prior daily snapshot.
Management fell by 9.7 points (from 31.4 to 21.7).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.